---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-008833"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:37:37.142668+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals announces SMC recommendation to escalate to third dose cohort in PH-762 Phase 1b trial

## Summary
- Safety Monitoring Committee reviewed safety data from second dose cohort and recommended escalation to next dose concentration.
- First two patients in second cohort showed complete response (100% tumor clearance) and partial response (90% clearance) at Day 36.
- No dose-limiting toxicities or serious adverse events reported in participants receiving intratumoral PH-762.
- PH-762 is being studied for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma in Phase 1b trial.

## SEC filing metadata
- accession: 0001683168-24-008833
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824008833/0001683168-24-008833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824008833/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-008833
- JSON: https://secwatch.observer/filing/0001683168-24-008833.json
- Plain text: https://secwatch.observer/filing/0001683168-24-008833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.